Cidara Therapeutics Inc (CDTX)
20.68
+3.23
(+18.51%)
USD |
NASDAQ |
Nov 22, 16:00
18.63
-2.05
(-9.91%)
After-Hours: 16:39
Cidara Therapeutics Max Drawdown (5Y): 95.11% for Oct. 31, 2024
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| October 31, 2024 | 95.11% |
| September 30, 2024 | 95.11% |
| August 31, 2024 | 95.11% |
| July 31, 2024 | 95.11% |
| June 30, 2024 | 95.11% |
| May 31, 2024 | 95.11% |
| April 30, 2024 | 95.11% |
| March 31, 2024 | 95.11% |
| February 29, 2024 | 95.11% |
| January 31, 2024 | 95.11% |
| December 31, 2023 | 95.11% |
| November 30, 2023 | 95.11% |
| October 31, 2023 | 95.11% |
| September 30, 2023 | 95.11% |
| August 31, 2023 | 95.11% |
| July 31, 2023 | 95.11% |
| June 30, 2023 | 95.11% |
| May 31, 2023 | 95.11% |
| April 30, 2023 | 95.11% |
| March 31, 2023 | 95.11% |
| February 28, 2023 | 95.11% |
| January 31, 2023 | 95.11% |
| December 31, 2022 | 95.11% |
| November 30, 2022 | 95.11% |
| October 31, 2022 | 95.11% |
| Date | Value |
|---|---|
| September 30, 2022 | 95.11% |
| August 31, 2022 | 95.11% |
| July 31, 2022 | 95.11% |
| June 30, 2022 | 95.11% |
| May 31, 2022 | 95.11% |
| April 30, 2022 | 93.38% |
| March 31, 2022 | 93.38% |
| February 28, 2022 | 93.38% |
| January 31, 2022 | 93.38% |
| December 31, 2021 | 92.76% |
| November 30, 2021 | 92.76% |
| October 31, 2021 | 92.76% |
| September 30, 2021 | 92.76% |
| August 31, 2021 | 92.76% |
| July 31, 2021 | 92.76% |
| June 30, 2021 | 92.76% |
| May 31, 2021 | 92.76% |
| April 30, 2021 | 92.76% |
| March 31, 2021 | 92.76% |
| February 28, 2021 | 92.76% |
| January 31, 2021 | 92.76% |
| December 31, 2020 | 92.76% |
| November 30, 2020 | 92.76% |
| October 31, 2020 | 92.76% |
| September 30, 2020 | 92.76% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
92.76%
Minimum
Nov 2019
95.11%
Maximum
May 2022
93.97%
Average
94.24%
Median
Max Drawdown (5Y) Benchmarks
| Biomarin Pharmaceutical Inc | 52.14% |
| Arbutus Biopharma Corp | 95.31% |
| GlycoMimetics Inc | 98.15% |
| FibroGen Inc | 99.46% |
| Cue Biopharma Inc | -- |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -36.77 |
| Beta (5Y) | 0.9944 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 87.90% |
| Historical Sharpe Ratio (5Y) | -0.2723 |
| Historical Sortino (5Y) | -0.6674 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 33.02% |